Sex differences in Alzheimer disease—the gateway to precision medicine
Alzheimer disease (AD) is characterized by wide heterogeneity in cognitive and behavioural
syndromes, risk factors and pathophysiological mechanisms. Addressing this phenotypic …
syndromes, risk factors and pathophysiological mechanisms. Addressing this phenotypic …
Understanding the impact of sex and gender in Alzheimer's disease: a call to action
Introduction Precision medicine methodologies and approaches have advanced our
understanding of the clinical presentation, development, progression, and management of …
understanding of the clinical presentation, development, progression, and management of …
APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia
The E4 allele of the apolipoprotein E gene (APOE) has been established as a genetic risk
factor for many diseases including cardiovascular diseases and Alzheimer's disease (AD) …
factor for many diseases including cardiovascular diseases and Alzheimer's disease (AD) …
Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences
With the aging of the population, the burden of Alzheimer's disease (AD) is rapidly
expanding. More than 5 million people in the US alone are affected with AD and this number …
expanding. More than 5 million people in the US alone are affected with AD and this number …
Sex modifies the APOE‐related risk of develo** Alzheimer disease
Objective The APOE4 allele is the strongest genetic risk factor for sporadic Alzheimer
disease (AD). Case–control studies suggest the APOE4 link to AD is stronger in women. We …
disease (AD). Case–control studies suggest the APOE4 link to AD is stronger in women. We …
Age, APOE and sex: triad of risk of Alzheimer's disease
Age, apolipoprotein E ε4 (APOE) and chromosomal sex are well-established risk factors for
late-onset Alzheimer's disease (LOAD; AD). Over 60% of persons with AD harbor at least …
late-onset Alzheimer's disease (LOAD; AD). Over 60% of persons with AD harbor at least …
ApoE4: an emerging therapeutic target for Alzheimer's disease
M Safieh, AD Korczyn, DM Michaelson - BMC medicine, 2019 - Springer
Background The growing body of evidence indicating the heterogeneity of Alzheimer's
disease (AD), coupled with disappointing clinical studies directed at a fit-for-all therapy …
disease (AD), coupled with disappointing clinical studies directed at a fit-for-all therapy …
Sex and the development of Alzheimer's disease
CJ Pike - Journal of neuroscience research, 2017 - Wiley Online Library
Men and women exhibit differences in the development and progression of Alzheimer's
disease (AD). The factors underlying the sex differences in AD are not well understood. This …
disease (AD). The factors underlying the sex differences in AD are not well understood. This …
Alzheimer's disease genetics: from the bench to the clinic
Alzheimer's disease (AD) is a clinically heterogeneous neurodegenerative disease with a
strong genetic component. Several genes have been associated with AD risk for nearly 20 …
strong genetic component. Several genes have been associated with AD risk for nearly 20 …
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception
MW Weiner, DP Veitch, PS Aisen, LA Beckett… - Alzheimer's & …, 2013 - Elsevier
Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing,
longitudinal, multicenter study designed to develop clinical, imaging, genetic, and …
longitudinal, multicenter study designed to develop clinical, imaging, genetic, and …